vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and TripAdvisor, Inc. (TRIP). Click either name above to swap in a different company.
TripAdvisor, Inc. is the larger business by last-quarter revenue ($411.0M vs $281.3M, roughly 1.5× Guardant Health, Inc.). TripAdvisor, Inc. runs the higher net margin — -9.2% vs -45.7%, a 36.4% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 0.0%). Guardant Health, Inc. produced more free cash flow last quarter ($-54.2M vs $-122.0M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 2.0%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Tripadvisor is an American company that operates online travel agencies, comparison shopping websites, and mobile apps with user-generated content.
GH vs TRIP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $411.0M |
| Net Profit | $-128.5M | $-38.0M |
| Gross Margin | 64.6% | 91.5% |
| Operating Margin | -43.0% | -8.3% |
| Net Margin | -45.7% | -9.2% |
| Revenue YoY | 39.4% | 0.0% |
| Net Profit YoY | -15.8% | -3900.0% |
| EPS (diluted) | $-1.01 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $411.0M | ||
| Q3 25 | $265.2M | $553.0M | ||
| Q2 25 | $232.1M | $529.0M | ||
| Q1 25 | $203.5M | $398.0M | ||
| Q4 24 | $201.8M | $411.0M | ||
| Q3 24 | $191.5M | $532.0M | ||
| Q2 24 | $177.2M | $497.0M | ||
| Q1 24 | $168.5M | $395.0M |
| Q4 25 | $-128.5M | $-38.0M | ||
| Q3 25 | $-92.7M | $53.0M | ||
| Q2 25 | $-99.9M | $36.0M | ||
| Q1 25 | $-95.2M | $-11.0M | ||
| Q4 24 | $-111.0M | $1.0M | ||
| Q3 24 | $-107.8M | $39.0M | ||
| Q2 24 | $-102.6M | $24.0M | ||
| Q1 24 | $-115.0M | $-59.0M |
| Q4 25 | 64.6% | 91.5% | ||
| Q3 25 | 64.7% | 92.6% | ||
| Q2 25 | 65.0% | 92.1% | ||
| Q1 25 | 63.3% | 93.2% | ||
| Q4 24 | 61.6% | 93.4% | ||
| Q3 24 | 61.1% | 92.5% | ||
| Q2 24 | 59.1% | 92.8% | ||
| Q1 24 | 61.2% | 93.7% |
| Q4 25 | -43.0% | -8.3% | ||
| Q3 25 | -37.3% | 12.7% | ||
| Q2 25 | -45.9% | 11.2% | ||
| Q1 25 | -54.6% | -3.8% | ||
| Q4 24 | -62.4% | 0.2% | ||
| Q3 24 | -61.3% | 13.2% | ||
| Q2 24 | -56.8% | 7.2% | ||
| Q1 24 | -59.2% | -3.8% |
| Q4 25 | -45.7% | -9.2% | ||
| Q3 25 | -35.0% | 9.6% | ||
| Q2 25 | -43.0% | 6.8% | ||
| Q1 25 | -46.8% | -2.8% | ||
| Q4 24 | -55.0% | 0.2% | ||
| Q3 24 | -56.3% | 7.3% | ||
| Q2 24 | -57.9% | 4.8% | ||
| Q1 24 | -68.2% | -14.9% |
| Q4 25 | $-1.01 | $-0.32 | ||
| Q3 25 | $-0.74 | $0.43 | ||
| Q2 25 | $-0.80 | $0.28 | ||
| Q1 25 | $-0.77 | $-0.08 | ||
| Q4 24 | $-0.90 | $0.03 | ||
| Q3 24 | $-0.88 | $0.27 | ||
| Q2 24 | $-0.84 | $0.17 | ||
| Q1 24 | $-0.94 | $-0.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $1.0B |
| Total DebtLower is stronger | $1.5B | $819.0M |
| Stockholders' EquityBook value | $-99.3M | $645.0M |
| Total Assets | $2.0B | $2.6B |
| Debt / EquityLower = less leverage | — | 1.27× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $1.0B | ||
| Q3 25 | $580.0M | $1.2B | ||
| Q2 25 | $629.1M | $1.2B | ||
| Q1 25 | $698.6M | $1.2B | ||
| Q4 24 | $525.5M | $1.1B | ||
| Q3 24 | $585.0M | $1.1B | ||
| Q2 24 | $933.7M | $1.2B | ||
| Q1 24 | $1.0B | $1.2B |
| Q4 25 | $1.5B | $819.0M | ||
| Q3 25 | $1.1B | $821.0M | ||
| Q2 25 | $1.1B | $822.0M | ||
| Q1 25 | $1.1B | $1.2B | ||
| Q4 24 | $1.1B | $831.0M | ||
| Q3 24 | — | $832.0M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $645.0M | ||
| Q3 25 | $-354.5M | $707.0M | ||
| Q2 25 | $-305.5M | $627.0M | ||
| Q1 25 | $-250.8M | $643.0M | ||
| Q4 24 | $-139.6M | $943.0M | ||
| Q3 24 | $-60.1M | $944.0M | ||
| Q2 24 | $-1.6M | $857.0M | ||
| Q1 24 | $68.3M | $825.0M |
| Q4 25 | $2.0B | $2.6B | ||
| Q3 25 | $1.3B | $2.8B | ||
| Q2 25 | $1.3B | $2.9B | ||
| Q1 25 | $1.3B | $2.8B | ||
| Q4 24 | $1.5B | $2.6B | ||
| Q3 24 | $1.5B | $2.7B | ||
| Q2 24 | $1.6B | $2.8B | ||
| Q1 24 | $1.7B | $2.7B |
| Q4 25 | — | 1.27× | ||
| Q3 25 | — | 1.16× | ||
| Q2 25 | — | 1.31× | ||
| Q1 25 | — | 1.81× | ||
| Q4 24 | — | 0.88× | ||
| Q3 24 | — | 0.88× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $-103.0M |
| Free Cash FlowOCF − Capex | $-54.2M | $-122.0M |
| FCF MarginFCF / Revenue | -19.3% | -29.7% |
| Capex IntensityCapex / Revenue | 9.9% | 4.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $163.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $-103.0M | ||
| Q3 25 | $-35.4M | $44.0M | ||
| Q2 25 | $-60.3M | $202.0M | ||
| Q1 25 | $-62.7M | $102.0M | ||
| Q4 24 | $-64.5M | $-3.0M | ||
| Q3 24 | $-51.1M | $-43.0M | ||
| Q2 24 | $-94.0M | $51.0M | ||
| Q1 24 | $-30.3M | $139.0M |
| Q4 25 | $-54.2M | $-122.0M | ||
| Q3 25 | $-45.8M | $25.0M | ||
| Q2 25 | $-65.9M | $177.0M | ||
| Q1 25 | $-67.1M | $83.0M | ||
| Q4 24 | $-83.4M | $-26.0M | ||
| Q3 24 | $-55.3M | $-63.0M | ||
| Q2 24 | $-99.1M | $36.0M | ||
| Q1 24 | $-37.2M | $123.0M |
| Q4 25 | -19.3% | -29.7% | ||
| Q3 25 | -17.3% | 4.5% | ||
| Q2 25 | -28.4% | 33.5% | ||
| Q1 25 | -33.0% | 20.9% | ||
| Q4 24 | -41.3% | -6.3% | ||
| Q3 24 | -28.9% | -11.8% | ||
| Q2 24 | -55.9% | 7.2% | ||
| Q1 24 | -22.1% | 31.1% |
| Q4 25 | 9.9% | 4.6% | ||
| Q3 25 | 3.9% | 3.4% | ||
| Q2 25 | 2.4% | 4.7% | ||
| Q1 25 | 2.2% | 4.8% | ||
| Q4 24 | 9.4% | 5.6% | ||
| Q3 24 | 2.2% | 3.8% | ||
| Q2 24 | 2.9% | 3.0% | ||
| Q1 24 | 4.1% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.83× | ||
| Q2 25 | — | 5.61× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -3.00× | ||
| Q3 24 | — | -1.10× | ||
| Q2 24 | — | 2.13× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
TRIP
| Third Party | $327.0M | 80% |
| The Fork | $58.0M | 14% |
| Other | $26.0M | 6% |
